« great prices and quality products well packaged and delivered to UK, Scotland without issues ...»
« Very professional. Easy and prompt communication. Received my order after days. Highly recomm ...»
I very satisfied it
« Hi thank you so mu ...»
Jennifer New York
sceptical at firs...
« I was unsure of using this service but I am glad I did, Yurity is great to deal with and my g ...»
« Very good deal, fast shipping, very kind, great friends, I will buy again, a 10 !!!»
Perfect, all is c...
« Just recieved my De-nol. It's take 10 days from order. I'm very satisfied of you guys. Thank ...»
« Just recieved my De-nol. It's take 10 days from order. I'm very satisfied rfom you guys. Than ...»
just received my ...
just received my order this m ...»
Patrice... Livry G...
« Hi, today my friend has received the package and it's all right. No damages and no problems a ...»
Marcello S. Arse...
« Hello, I have received the package, I will recommend you without hesitation, thank you for ev ...»
Producer: Merz Pharma, Germany
The trade name of the drug in Europe: Axura®, Ebixa®, in USA - Namenda®, in Russia and in the countries of Latin America, Akatinol®
Composition: One tablet, coated liner contains:Active substance: Hidrohlorids memantine 10 mgExcipients: Lactose 174,75 mgCellulose microcrystalline 52,10 mgOf colloidal silicon dioxide 1.25 mgTalc of 11.15 mgMagnesium stearate 0.75 mgShell:Methacrylic acid copolymer 1,446 mgSodium lauryl sulphate 0.010 mgTalc 0,350 mg
Pharmacological group:Non-competitive antagonist of NMDA receptors
Code ATX: N06DX01
Description: Tablets, film-coated tablets white color, oblong, lenticular, with the risk on each side.
Indications for use:Degenerative dementia (Alzheimer's type), vascular dementia, mixed dementia of all degrees of severity. Alzheimer's disease, pick's diseaseThe syndrome of dementia, depression, dementiThe weakening of memory, ability to concentrate and ability to learnDiseases that require increased vigilence, for example, after traumatic brain injury, open or closed brain injury, comatose States, room
Pharmacodynamics. Being a non-competitive antagonist of N-methyl-D-aspartate (NMDA) receptors, exerts a modulatory action on glutamatergic system. Regulates ion transport, blocks the calcium channels normalizes the membrane potential, improves the process of transmission of nerve impulse.
Pharmacokinetics. After intake of rapidly and completely dissolves absorbed. The maximum concentration in plasma is achieved within 2-6 hours. When the normal renal function of drug accumulation is not observed. The elimination of two-phase flows. The half-life is in the first phase, 4-9 hours, the second - 40-65 hours. Excreted in the urine.PharmacokineticsAfter intake of rapidly and completely dissolves absorbed. The maximum concentration in plasma is achieved within 2-6 hours. When the normal renal function of drug accumulation is not observed. The elimination of two-phase flows. The half-life is in the first phase, 4-9 hours, the second - 40-65 hours. Excreted in the urine.
Method of application and doses. The dosage regimen set individually. To start treatment with the appointment of the minimum effective dose. Adults with the syndrome of dementia is prescribed during 1st weeks of therapy at a dose of 5 mg/day, for 2 weeks in the dose of 10 mg/day. Within 3-weeks - at a dose of 15-20 mg/day. If necessary, may further increase weekly dose by 10 mg until a daily dose of 30 mg. the Optimal dose is achieved gradually, with increasing doses each week.
Side effects. Dizziness, fatigue, anxiety, irritability, nausea.
Contraindications. Expressed violations kidney function; severe disturbances of liver function; serious dysfunction of the Central nervous system; pregnancy, breastfeeding, children under 18 years (insufficient data). Be wary appoint patients with thyrotoxicosis, epilepsy, convulsions (including history), myocardial infarction, congestive heart failure.
Overdose. Perhaps the increasing incidence described side effects.
Special instructions. For patients with impaired renal function the dosage regimen set individually, depending on clinical efficacy, under control of renal function during treatment. In a joint application Akatinol Memantine may change the action dantrolene or baclofen, so doses should be selected individually. In patients with Alzheimer's disease at the stage of moderate and severe dementia usually impaired ability to drive vehicles or operate machinery.
Release form. Tablets, film-coated, 20 mg.There are 56 tablets in blister from PVC film and aluminum foil. Instructions for use is placed in cardboard pack.
Shelf life. 4 years.Do not use after expiration date.
Storage conditions. At temperatures above 25 C in places inaccessible to children.